Cargando…
Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes
BACKGROUND: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275169/ https://www.ncbi.nlm.nih.gov/pubmed/35818084 http://dx.doi.org/10.1186/s40001-022-00731-x |
_version_ | 1784745436974678016 |
---|---|
author | Samimi, Sahar Rajabzadeh, Sahar Rabizadeh, Soghra Nakhjavani, Manouchehr Nakhaei, Pooria Avanaki, Foroogh Alborzi Esteghamati, Alireza |
author_facet | Samimi, Sahar Rajabzadeh, Sahar Rabizadeh, Soghra Nakhjavani, Manouchehr Nakhaei, Pooria Avanaki, Foroogh Alborzi Esteghamati, Alireza |
author_sort | Samimi, Sahar |
collection | PubMed |
description | BACKGROUND: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduce the risk of morbidity and mortality. This study investigated the association between the atherogenic index of plasma (AIP) and MAFLD in patients with T2D. METHOD: A retrospective case–control study was conducted and medical records of patients with T2D were assessed. The baseline characteristics, anthropometric indices, laboratory measurements including liver functions tests, fasting blood sugar, HbA1C, lipid profile were documented. RESULTS: Out of 2547 patients with T2D, 824 (32.4%) had MAFLD. The multivariate logistic regression analysis showed a significant difference in female-to-male ratio (1.11 vs. 1.33, OR = 0.347, P-value < 0.001), ALT (42.5 ± 28.1 vs. 22.4 ± 11.1, OR = 1.057, P-value < 0.001), and AIP (0.6 ± 0.3 vs. 0.5 ± 0.3, OR = 5.057, P-value < 0.001) between MAFLD and non-MAFLD groups, respectively. According to the AIP quartile, the prevalence of MAFLD increased significantly in patients with higher AIP quartiles (P-value < 0.001). Also, we found a cut-off of 0.54 for AIP in predicting MAFLD in patients with T2D (sensitivity = 57.8%, specificity = 54.4%). CONCLUSION: In this study, we found that AIP is a good and independent predictor for MAFLD in patients with T2D which could help physicians in early diagnosis and follow-up of patients with T2D. |
format | Online Article Text |
id | pubmed-9275169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92751692022-07-13 Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes Samimi, Sahar Rajabzadeh, Sahar Rabizadeh, Soghra Nakhjavani, Manouchehr Nakhaei, Pooria Avanaki, Foroogh Alborzi Esteghamati, Alireza Eur J Med Res Research BACKGROUND: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduce the risk of morbidity and mortality. This study investigated the association between the atherogenic index of plasma (AIP) and MAFLD in patients with T2D. METHOD: A retrospective case–control study was conducted and medical records of patients with T2D were assessed. The baseline characteristics, anthropometric indices, laboratory measurements including liver functions tests, fasting blood sugar, HbA1C, lipid profile were documented. RESULTS: Out of 2547 patients with T2D, 824 (32.4%) had MAFLD. The multivariate logistic regression analysis showed a significant difference in female-to-male ratio (1.11 vs. 1.33, OR = 0.347, P-value < 0.001), ALT (42.5 ± 28.1 vs. 22.4 ± 11.1, OR = 1.057, P-value < 0.001), and AIP (0.6 ± 0.3 vs. 0.5 ± 0.3, OR = 5.057, P-value < 0.001) between MAFLD and non-MAFLD groups, respectively. According to the AIP quartile, the prevalence of MAFLD increased significantly in patients with higher AIP quartiles (P-value < 0.001). Also, we found a cut-off of 0.54 for AIP in predicting MAFLD in patients with T2D (sensitivity = 57.8%, specificity = 54.4%). CONCLUSION: In this study, we found that AIP is a good and independent predictor for MAFLD in patients with T2D which could help physicians in early diagnosis and follow-up of patients with T2D. BioMed Central 2022-07-11 /pmc/articles/PMC9275169/ /pubmed/35818084 http://dx.doi.org/10.1186/s40001-022-00731-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Samimi, Sahar Rajabzadeh, Sahar Rabizadeh, Soghra Nakhjavani, Manouchehr Nakhaei, Pooria Avanaki, Foroogh Alborzi Esteghamati, Alireza Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title_full | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title_fullStr | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title_full_unstemmed | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title_short | Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
title_sort | atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275169/ https://www.ncbi.nlm.nih.gov/pubmed/35818084 http://dx.doi.org/10.1186/s40001-022-00731-x |
work_keys_str_mv | AT samimisahar atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT rajabzadehsahar atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT rabizadehsoghra atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT nakhjavanimanouchehr atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT nakhaeipooria atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT avanakiforooghalborzi atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes AT esteghamatialireza atherogenicindexofplasmaisanindependentpredictorofmetabolicassociatedfattyliverdiseaseinpatientswithtype2diabetes |